Figure 2.

Relative rates of asthma exacerbations across subgroups in pooled studies of omalizumab in patients with moderate-to-severe asthma: point estimates and 95% confidence intervals for asthma exacerbation rate ratios (omalizumab: control) from Poisson regression models. Reproduced, with permission, from Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60:302–308.³⁵ Copyright © 2005 Blackwell Publishing.

Abbreviations: FEV₁, forced expiratory volume in 1 second; IgE, immunoglobin E.